Skip to main
MGX

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Therapeutics Inc is focused on developing advanced genomic editing technologies aimed at creating curative treatments for various disorders, with a robust pipeline addressing conditions such as Hemophilia A and cardiovascular diseases. The company’s gene editing approach has demonstrated strong efficacy, achieving durable FVIII levels of 80% over a 19-month period in non-human primates, highlighting the potential for effective long-term treatment solutions. Furthermore, Metagenomi's dual strategy of advancing its pipeline while exploring technology out-licensing for ex vivo cell therapy positions it favorably within the expanding genetic therapeutics market.

Bears say

Metagenomi Therapeutics reported a substantial net loss of $19.9 million in its second quarter of 2025, equating to a loss of $0.54 per share. The company’s stock trades significantly below its cash value, suggesting potential for upside; however, this valuation is undercut by significant operational risks, including possible delays in clinical assessments and unfavorable clinical outcomes from trials for key candidates such as Hemophilia A and TTR. Additionally, there is an ongoing concern regarding potential long-term dilution, adding to the uncertainties surrounding the company's future financial performance.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.